CANF Stock Overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Can-Fite BioPharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.98 |
| 52 Week High | ₪3.33 |
| 52 Week Low | ₪1.69 |
| Beta | 0.91 |
| 1 Month Change | -11.21% |
| 3 Month Change | -0.25% |
| 1 Year Change | 11.24% |
| 3 Year Change | -91.08% |
| 5 Year Change | -97.49% |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| CANF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.5% | -3.2% |
| 1Y | 11.2% | -3.7% | 19.3% |
Return vs Industry: CANF exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: CANF underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| CANF volatility | |
|---|---|
| CANF Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CANF has not had significant price volatility in the past 3 months.
Volatility Over Time: CANF's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 8 | Motti Farbstein | www.canfite.com |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
Can-Fite BioPharma Ltd. Fundamentals Summary
| CANF fundamental statistics | |
|---|---|
| Market cap | US$10.32m |
| Earnings (TTM) | -US$7.63m |
| Revenue (TTM) | US$743.00k |
13.9x
P/S Ratio-1.4x
P/E RatioIs CANF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANF income statement (TTM) | |
|---|---|
| Revenue | US$743.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$743.00k |
| Other Expenses | US$8.38m |
| Earnings | -US$7.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0051 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,027.46% |
| Debt/Equity Ratio | 0% |
How did CANF perform over the long term?
See historical performance and comparison